DK3024474T3 - Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist - Google Patents

Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist Download PDF

Info

Publication number
DK3024474T3
DK3024474T3 DK14748451.3T DK14748451T DK3024474T3 DK 3024474 T3 DK3024474 T3 DK 3024474T3 DK 14748451 T DK14748451 T DK 14748451T DK 3024474 T3 DK3024474 T3 DK 3024474T3
Authority
DK
Denmark
Prior art keywords
adrenor
desmopressine
beta
combination
receptor agonist
Prior art date
Application number
DK14748451.3T
Other languages
Danish (da)
English (en)
Inventor
Seymour H Fein
Samuel Herschkowitz
Original Assignee
Serenity Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serenity Pharmaceuticals Llc filed Critical Serenity Pharmaceuticals Llc
Application granted granted Critical
Publication of DK3024474T3 publication Critical patent/DK3024474T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK14748451.3T 2013-07-23 2014-07-23 Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist DK3024474T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361857431P 2013-07-23 2013-07-23
PCT/US2014/047899 WO2015013454A1 (en) 2013-07-23 2014-07-23 Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist

Publications (1)

Publication Number Publication Date
DK3024474T3 true DK3024474T3 (da) 2022-03-28

Family

ID=51299056

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14748451.3T DK3024474T3 (da) 2013-07-23 2014-07-23 Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist

Country Status (11)

Country Link
US (2) US9814753B2 (OSRAM)
EP (1) EP3024474B1 (OSRAM)
JP (2) JP2016525548A (OSRAM)
KR (3) KR20240015735A (OSRAM)
CN (1) CN105579057A (OSRAM)
AU (1) AU2014293141A1 (OSRAM)
CA (1) CA2919198A1 (OSRAM)
DK (1) DK3024474T3 (OSRAM)
ES (1) ES2910361T3 (OSRAM)
MX (1) MX2016001030A (OSRAM)
WO (1) WO2015013454A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
ES2929471T3 (es) 2009-06-18 2022-11-29 Acerus Pharmaceuticals Usa Llc Administración segura de desmopresina
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AU2014293140A1 (en) 2013-07-23 2016-03-03 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
EP3220942B1 (en) 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
WO2017210700A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
KR101877834B1 (ko) * 2017-04-27 2018-07-12 주식회사 다산제약 미라베그론의 신규한 염 및 이의 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
IL101243A (en) 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
CA2312839C (en) 1997-12-02 2008-01-15 Lisbeth Illum Compositions for nasal administration
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
WO2002055128A2 (en) 2000-11-30 2002-07-18 Biovalve Technologies Inc Fluid delivery and measurement systems and methods
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
NZ539577A (en) * 2002-11-07 2007-06-29 Astellas Pharma Inc Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
JP5596252B2 (ja) * 2003-11-10 2014-09-24 アラーガン、インコーポレイテッド 低用量デスモプレシンを含有する医薬組成物
CN101829319A (zh) 2003-12-08 2010-09-15 Cpex药品公司 用于胰岛素治疗的药用组合物及方法
DE102005016981A1 (de) 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
WO2007072156A1 (en) 2005-12-21 2007-06-28 Pfizer Products Inc. Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
WO2007083640A1 (ja) * 2006-01-18 2007-07-26 Kyorin Pharmaceutical Co., Ltd. 頻尿及び尿失禁の予防又は治療剤
CA2988753A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
CN101648017A (zh) 2008-08-12 2010-02-17 许洁 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物
EP2361092A4 (en) 2008-09-04 2012-07-11 Anthony I Rozmanith HEALTH CARE
US20100160214A1 (en) 2008-12-22 2010-06-24 Serenity Pharmaceuticals Corporation Desmopressin composition
BRPI0923557A2 (pt) * 2008-12-22 2016-01-26 Allergan Inc administração de desmopressina intranasal
ES2929471T3 (es) * 2009-06-18 2022-11-29 Acerus Pharmaceuticals Usa Llc Administración segura de desmopresina
IN2012DN02782A (OSRAM) * 2009-10-07 2015-09-18 Merck Sharp & Dohme
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9522129B2 (en) * 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
EP2672958A1 (en) 2011-02-08 2013-12-18 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
AU2013235518B2 (en) 2012-03-19 2017-03-02 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
GB201312155D0 (en) 2013-07-05 2013-08-21 Ucl Business Plc Therapeutic invention
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
AU2014293140A1 (en) 2013-07-23 2016-03-03 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
US20160220489A1 (en) 2013-09-03 2016-08-04 G2B Pharma Inc. Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions
EP3220942B1 (en) 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist

Also Published As

Publication number Publication date
JP7219736B2 (ja) 2023-02-08
WO2015013454A1 (en) 2015-01-29
EP3024474B1 (en) 2022-01-05
EP3024474A1 (en) 2016-06-01
US10568927B2 (en) 2020-02-25
US20150031613A1 (en) 2015-01-29
JP2016525548A (ja) 2016-08-25
KR20160033220A (ko) 2016-03-25
JP2020109122A (ja) 2020-07-16
US20180289769A1 (en) 2018-10-11
AU2014293141A1 (en) 2016-02-18
ES2910361T3 (es) 2022-05-12
KR20210103589A (ko) 2021-08-23
MX2016001030A (es) 2016-10-07
KR20240015735A (ko) 2024-02-05
CA2919198A1 (en) 2015-01-29
US9814753B2 (en) 2017-11-14
CN105579057A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
GB201313377D0 (en) T cell receptors
DK2984424T3 (da) Forbedringer i køleskabe
EP2889350A4 (en) ADHESIVE COMPOSITION
GB201314404D0 (en) T Cell Receptors
DK3024474T3 (da) Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
DK2943549T3 (da) Synergistisk h2s-scavenger-sammensætning
DK3027750T3 (da) Biokatalytisk sammensætning
DK3044389T3 (da) Vinduespost-tværstykke-konstruktion
DK3019894T3 (da) In situ accelerometer-kalibrering
ZA201604490B (en) S1p3 antagonists
GB201322430D0 (en) T cell receptors
GB201305118D0 (en) Blends
IL243730A0 (en) Vasopressin-2 receptor agonists
FI20135236A7 (fi) Haudutin
GB201312010D0 (en) Receptor Agonists
GB201418840D0 (en) In german
EP2985312A4 (en) AGGREGATE AND COMPOSITION
FR3007434B1 (fr) Structure de cabanon en kit
GB201304666D0 (en) Dopamine receptor antagonist
DK3082855T3 (da) Sammensætning
FR3013565B1 (fr) Bagage a peson
GB201304105D0 (en) Agonist
BR302013006435S1 (pt) Configuração aplicada em tênis
BR302013005853S1 (pt) Configuração aplicada em tênis
BR302013004794S1 (pt) Configuração aplicada em tênis